Clinical Trial Update: Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329) [Phase 3]

View source ↗

Summary

Phase 3 trial of MK-217A-alendronate sodium 70-mg/Vitamin D3 5600 IU combination tablet in osteoporosis has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet

Snippet

Sponsor: Organon and Co | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2014-01-22